Study of Azacitidine，Venetoclax，and Flumatinib in Newly Diagnosed Ph-positive Acute Leukemia and CML-AP/BP Patients

Exclusion Criteria

• •1. Patients with another malignant disease.
• •2. Patients has participated in or participating in other clinical trials.
• •3. Patients with uncontrolled active infection.
• •4. Patients with left ventricular ejection fraction \< 0.5 by echocardiography or grade III/IV cardiovascular dysfunction according to the New York Heart Association Classification.
• •5. Patients with HIV infection, active tuberculosis infection, or active hepatitis B or hepatitis C infection.
• •6. Patients with uncontrolled active bleeding.
• •7. Patients with history of previous chemotherapy or target therapy (except for oral hydroxyurea and/or leukopheresis for lowering white blood cell counts).
• •8. Pregnant and lactating women; patients of childbearing potential should be willing to practice methods of contraception throughout the study period.
• •9. Patients with other commodities that the investigators considered not suitable for the enrollment.